Pozelimab · Veopoz

Monoclonal antibody

Approvedregulatory verdict

Evidence outlook

Approved: adult and pediatric patients 1 year of age and older with CD55-deficient protein-losing... (FDA)

This approval is for an indication outside this terminal's covered markets; the covered program shown here is investigational in the US. Regulatory approval supersedes design-level evidence grading for the approved use.

Also in development:Age-Related Macular Degeneration · Phase 3Generalized Myasthenia Gravis · Phase 3

Also approved (1)
US
  • VEOPOZ is indicated for the treatment of adult and pediatric patients 1 year of age and older with CD55-deficient protein-losing enteropathy (PLE), also known as CHAPLE disease.
Product first approved 2023Outside this platform's coverageFDA label

Source for the program status

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 3 (7)
Age-Related Macular Degeneration
NCT06541704 · Regeneron Pharmaceuticals
2024-10-30 – 2033-04-09 · Age-related Macular Degeneration (AMD), Geographic Atrophy (GA)
What this study did
Generalized Myasthenia Gravis
NCT05070858 · Regeneron Pharmaceuticals
2021-12-14 – 2028-11-11 · Generalized Myasthenia Gravis
What this study did
Paroxysmal Nocturnal Hemoglobinuria
NCT05131204 · Regeneron Pharmaceuticals
2022-10-06 – 2023-07-12 · Paroxysmal Nocturnal Hemoglobinuria
What this study did
NCT04162470 · Regeneron Pharmaceuticals
2019-12-03 – 2022-04-07 · Paroxysmal Nocturnal Hemoglobinuria
What this study did
Phase 2/3 (1)
Other / comorbidity
NCT04209634 · Regeneron Pharmaceuticals
2020-01-27 – 2024-05-02 · CD55-deficient Protein-losing Enteropathy, CHAPLE
What this study did
Phase 2 (3)
Paroxysmal Nocturnal Hemoglobinuria
NCT04811716 · Regeneron Pharmaceuticals
2021-07-29 – 2023-10-18 · Paroxysmal Nocturnal Hemoglobinuria
What this study did
NCT04888507 · Regeneron Pharmaceuticals
2021-07-08 – 2023-05-04 · Paroxysmal Nocturnal Hemoglobinuria
What this study did
NCT03946748 · Regeneron Pharmaceuticals
2019-05-16 – 2021-06-10 · Paroxysmal Nocturnal Hemoglobinuria (PNH)
What this study did
Phase 1 (6)
Age-Related Macular Degeneration
NCT07230834 · Regeneron Pharmaceuticals
2026-01-19 – 2028-07-03 · Geographic Atrophy (GA)
What this study did
Other / comorbidity
NCT06479863 · Austin Neuromuscular Center
2024-08-08 – 2027-08-30 · Sporadic Inclusion Body Myositis (sIBM), Idiopathic Inflammatory Myopathies
What this study did
NCT04601844 · Regeneron Pharmaceuticals
2020-11-16 – 2021-07-23 · Healthy
What this study did
NCT04491838 · Regeneron Pharmaceuticals
2020-08-03 – 2021-03-05 · Healthy Volunteer
What this study did
NCT03115996 · Regeneron Pharmaceuticals
2017-05-10 – 2018-08-31 · Healthy Volunteers
What this study did
Phase 4 (1)

Competitive landscape

6 other tracked programmes target this mechanism, 3 of them ahead of this one.

This drug's own stage for Generalized Myasthenia Gravis: Phase 3. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Pozelimab (Veopoz): this drugPhase 3Monoclonal antibodyComplement C5not yet gradedNo reviewed efficacy summary in this indication
Eculizumab (Soliris)ApprovedMonoclonal antibodyComplement C5Partial signal
NCT01997229: Myasthenia Gravis Activities of Daily Living Profile (MG-ADL): Change From Baseline in MG-ADL Total Score at Week 26 by Worst-Rank Analysis of Covariance (ANCOVA) (End of study (Week 26)): Eculizumab 56.6 scores on a scale (Standard Error 4.53) | Placebo 68.3 scores on a scale (Standard Error 4.49) missed
Efgartigimod Alfa (Vyvgart)ApprovedAntibody fragmentFcRnnot yet gradedNo reviewed efficacy summary in this indication
Efgartigimod Alfa And Hyaluronidase (Vyvgart Hytrulo)ApprovedAntibody fragmentFcRnnot yet gradedNo reviewed efficacy summary in this indication
InebilizumabApprovedMonoclonal antibodyCD19Reliable signal
NCT04524273: Change From Baseline at Week 26 in Myasthenia Gravis Activities of Daily Living (MG-ADL) Score in the Overall Study Population (Baseline and Week 26): Overall: Placebo -2.2 Score on a scale (95% CI -3 to -1.5) | Overall: Inebilizumab 300 mg -4.2 Score on a scale (95% CI -4.9 to -3.4)
Ravulizumab (Ultomiris)ApprovedMonoclonal antibodyComplement C5not yet gradedNo reviewed efficacy summary in this indication
CemdisiranPhase 3RNA / oligonucleotideComplement C5not yet gradedNo reviewed efficacy summary in this indication
Gefurulimab (Klygefa)Phase 3Antibody-derived scaffoldComplement C5not yet gradedNo reviewed efficacy summary in this indication
Iptacopan (Fabhalta)Phase 3Small moleculeComplement Factor Bnot yet gradedNo reviewed efficacy summary in this indication
TelitaciceptPhase 3Protein / enzyme therapeuticBAFF / APRILnot yet gradedNo reviewed efficacy summary in this indication
AritinerceptPhase 1/2Protein / enzyme therapeuticBAFF / APRILnot yet gradedNo reviewed efficacy summary in this indication

Upcoming events

(6 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Veopoz (Pozelimab) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (1)
May 2027 (1)
Phase 1Sporadic Inclusion Body Myositis (sIBM), Idiopathic Inflammatory MyopathiesRecruiting
Est. primary completion 2027-05-30 · NCT06479863 · CT.gov ↗
What to watch
2028 (3)
July 2028 (2)
Phase 1Age-Related Macular DegenerationRecruiting
Est. primary completion 2028-07-03 · NCT07230834 · CT.gov ↗
What to watch
Phase 3Age-Related Macular DegenerationRecruiting
Est. primary completion 2028-07-31 · NCT06541704 · CT.gov ↗
What to watch
October 2028 (1)
Phase 3Paroxysmal Nocturnal HemoglobinuriaRecruiting
Est. primary completion 2028-10-10 · NCT05744921 · CT.gov ↗
What to watch
2030 (2)
January 2030 (1)
Phase 3Paroxysmal Nocturnal HemoglobinuriaRecruiting
Est. primary completion 2030-01-18 · NCT07154745 · CT.gov ↗
What to watch
February 2030 (1)
Phase 4CHAPLE DiseaseRecruiting
Est. primary completion 2030-02-12 · NCT07142343 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(1)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

26 August 2025Topline resultNIMBLE Phase 3 (NCT05070858) in gMG: pozelimab + cemdisiran combination met its endpoints; cemdisiran monotherapy chosen for filing
Regeneron Pharmaceuticals, Inc. · Source ↗